Document:

EX-10.2

 Exhibit 10.2 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***].” 
 .OMB Approval
2700-0042 
  

							
	            AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	  	  

1. CONTRACT ID CODE            
	 	  
 PAGE OF PAGES

	  	N/A	 	    1    	 	    2    

											
	  

2. AMENDMENT/MODIFICATION NO.    

0009
	 	  

  3. EFFECTIVE DATE      

  [See block 16C, below]
	 	  

  4. REQUISITION/PURCHASE REQ. NO        

      
	 	  

5. PROJECT NO. (If applicable)

 N/A

											
	
6. ISSUED BY                   
              
	 	CODE  	 	 	 	7. ADMINISTERED BY (IF OTHER THAN ITEM 6)     	 	CODE    	 	  N/A
  

	  

National Institutes of Health

National Institute of Allergy and Infectious Diseases

DEA, Office of Acquisitions

Room 3B49, MSC 9821
 5601
Fishers Lane
 Bethesda, MD 20892-9821
  
	 	  
 MID RCB-B
	 	 	 	 

									
	  

8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State, and Zip 
Code)
 Pfenex, Inc.

10790 Roselle Street
 San
Diego, CA 92121
	 	  

☐   
	 	  
 9A. AMENDMENT OF SOLICITATION
NO.
  

	 	 	 	  
 9B. DATED
(SEE ITEM 11)
  

		 		 		 	  

☒  
	 	  

10A. MODIFICATION OF CONTRACT/ORDER    

NO. HHSN272201200033C
  

	 CODE:

 
	 	 	 	 FACILITY CODE:

 
	 	 	 	  
 10B. DATED
(SEE ITEM 13)
 09/27/2012
  

	 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF
SOLICITATIONS

 
 ☐  The above numbered, solicitation is amended as set
forth in item 14. The hour and date specified for receipt of Offers    ☐  is extended    ☐  is not extended. 

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 

(a) By completing Items 8 and 15, and returning one (1) copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer
submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers, FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE
SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and
this amendment, and is received prior to the opening hour and date specified. 
  

			
	12. ACCOUNTING AND APPROPRIATION DATA (If Required)
	
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO., AS DESCRIBED IN ITEM 14

	☐  	 	 A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:
(Specify Authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
  

	☐  	 	 B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO
REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43,103 (b).

 

	☒  	 	 C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO
PURSUANT TO AUTHORITY OF:
 Mutual Agreement of the Parties
  

	☐  	 	 D. OTHER (Specify type of modification and
authority)
  

	 
	E. IMPORTANT:
Contractor  ☐         is NOT    ☒    is required to sign this document and return 1 copies to the issuing office.
	 
	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract
subject matter where feasible.)
	 
	 PURPOSE: The
purpose of this modification is to update ARTICLE G.2. Key Personnel.
  

			
	 TOTAL FUNDS CURRENTLY OBLIGATED: $[***]

TOTAL ESTIMATED COST: $[***]
	 	 FUNDED THROUGH DATE: December 31, 2017 (Unchanged)

COMPLETION DATE: December 31, 2017 (Unchanged)

	  

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force
and effect.
  

							
	15A. NAME AND TITLE OF SIGNER	 	 	  	 16A. NAME
AND TITLE OF CONTRACTING OFFICER
 Michael P. Welsh
 Contracting
Officer, MID RCB-B, OA, DEA, NIAID, NIH, DHHS
  

	 15B. CONTRACTOR/OFFEROR

 
 /s/ Patrick Lucy

(Signature of person authorized to sign)
	 	 15C. DATE SIGNED

9/27/16
	  	 16B. UNITED STATES OF AMERICA

 
 /s/ Michael P. Welsh

(Signature of Contracting Officer)
  
	 	 16C. DATE SIGNED

9/28/16

  

					
	NSN 7540-01-152-8070	 	30-105	 	STANDARD FORM 30 (REV. 10-83)
	Previous Edition Unusable	 	Computer Generated	 	Prescribed by GSA
		 		 	FAR (48 CFR) 53.243

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

					
	  
 Contract No: HHSN272201200033C

 
	  	  
 Modification No: 09

 
	  	  
 
            Page 2 of 
 2
            
  

 

 ARTICLE G.2. KEY PERSONNEL (HHSAR 352.242-70 (January 2006) is hereby modified to update
key personnel as follows: 
  

			
	 Name
	  	 Title

	 [***]
	  	Principal Investigator
	
[***]                  
  
	  	Deputy Principle Investigator
	 [***]
	  	Clinician focused on pre-clinical and clinical studies
	 [***]
	  	Director Downstream Processing (DSP) and Analytical Biochemistry
	 [***]
	  	Project Manager
	 [***]
	  	Project Control Manager

  
  

HHS-556 
 [***] Certain information in this document has
been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.3

 Exhibit 10.3 

PFENEX INC. 
 EXECUTIVE
EMPLOYMENT AGREEMENT 
 This Executive Employment Agreement (the “Agreement”) is entered into by and between Pfenex
Inc. (the “Company”), and Steven S. Sandoval, Sr. (“Executive”). This Agreement will be effective as the date Executive commences employment with the Company (the “Effective Date”). It is
expected that the Effective Date will be September 26, 2016. 
 1. Duties and Scope of Employment. 

(a) Positions and Duties. Effective as of the Effective Date, Executive will serve as the Company’s Chief Manufacturing Officer.
Executive will render such business and professional services in the performance of Executive’s duties, consistent with Executive’s position within the Company, as will reasonably be assigned to Executive by the Company’s Chief
Executive Officer. The period of Executive’s employment under this Agreement is referred to herein as the “Employment Term.” 

(b) Obligations. During the Employment Term, Executive will perform Executive’s duties faithfully and to the best of
Executive’s ability and will devote Executive’s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for
any direct or indirect remuneration without the prior approval of the Company’s board of directors (the “Board”), except as provided in Schedule 1. 

2. At-Will Employment. The parties agree that Executive’s employment with the Company will be “at-will” employment and
may be terminated at any time with or without Cause or notice. Executive understands and agrees that neither Executive’s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the
basis for modification, amendment, or extension, by implication or otherwise, of Executive’s employment with the Company. However, as described in this Agreement, Executive may be entitled to severance benefits depending on the circumstances of
Executive’s termination of employment with the Company. 
 3. Compensation. 

(a) Base Salary. Effective as of the Effective Date, the Company will pay Executive an annual salary of $296,276 as compensation
for Executive’s employment services to the Company (the “Base Salary”). The Base Salary will be paid periodically in accordance with the Company’s normal payroll practices and be subject to the usual, required
withholdings. Executive’s annual salary will be subject to review and adjustments as may be made based upon the Company’s normal performance review practices. 

(b) Relocation Bonus. Executive will receive a one-time cash relocation bonus of $75,000, less applicable withholdings, payable
with on the first Company payroll date following the Effective Date (the “Relocation Bonus”), provided that Executive remains an employee of the Company on the date the Relocation Bonus is paid to Executive. Notwithstanding the
foregoing, if 

 
(i) Executive’s employment with the Company terminates due to Executive’s voluntary resignation other than for Good Reason prior to the first anniversary of the Effective Date, or (ii)
Executive does not relocate to the San Diego Metropolitan area prior to the first anniversary of the Effective Date, then, Executive must repay the gross amount of the Relocation Bonus to the Company within 30 days of earlier of the date
Executive’s employment with the Company terminates due to Executive’s voluntary resignation other than for Good Reason or the first anniversary of the Effective Date. 

(c) Target Bonus. Beginning with calendar year 2017, Executive will be eligible to receive an annual bonus of up to twenty-five
percent (25%) of Executive’s Base Salary upon achievement of performance objectives to be determined by the Board in its sole discretion (the “Target Bonus”). The Target Bonus, or any portion thereof, will be paid, less
applicable withholdings, as soon as practicable after the Board determines that the Target Bonus has been earned, but in no event shall the Target Bonus be paid after the later of (i) the fifteenth
(15th) day of the third (3rd) month following the close of the Company’s fiscal year in which the Target Bonus is earned or (ii)
March 15 following the calendar year in which the Target Bonus is earned. Executive’s Target Bonus will be subject to review and adjustments as may be made based upon the Company’s normal performance review practices. 

(d) Stock Option. Subject to the approval of the Board (or a committee thereof), Executive will be granted a nonstatutory stock
option to purchase 132,290 shares of the Company’s common stock at an exercise price per share equal to the fair market value on the date of grant (the “Option”). Subject to the accelerated vesting provisions set forth
herein, the Option will vest as to 25% of the shares subject to the Option one (1) year after the Effective Date, and as to 1/48th of the shares subject to the Option monthly thereafter on the same day of the month as the Effective Date (and if
there is no corresponding day, the last day of the month), so that the Option will be fully vested and exercisable four (4) years from the Option’s date of grant, subject to Executive continuing to provide services to the Company through the
relevant vesting dates. Except as provided herein, the Option will be subject to the terms and conditions of an equity incentive plan and related stock option agreement approved by the Board (or a committee thereof), including vesting
requirements (collectively, the “Equity Documents”). No right to any stock is earned or accrued until such time that vesting occurs, nor does the grant confer any right to continue vesting or employment. 

4. Employee Benefits. During the Employment Term, Executive will be entitled to participate in the employee benefit plans
currently and hereafter maintained by the Company of general applicability to other senior executives of the Company. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time. 

5. Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in
the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time. 

6. Severance. 
 (a)
Termination for other than Cause, Death or Disability Apart from a Change of Control. If, outside of the Change of Control Period, (i) the Company (or any parent or subsidiary or 

  
 -2- 

 
successor of the Company) terminates Executive’s employment with the Company other than for Cause, death or Disability, or (ii) the Executive resigns from such employment for Good Reason,
then, subject to Section 7, Executive will be entitled to receive: 
 (i) continuing payments of severance pay for a period of nine (9)
months at a rate equal to (x) the sum of (A) seventy-five percent (75%) of Executive’s Base Salary rate, as then in effect, plus (B) the sum of all performance bonuses paid to Executive for the Company’s fiscal year immediately
preceding the fiscal year in which Executive’s termination of employment occurs divided by (y) nine (9). The severance will be paid, less applicable withholdings, in installments over the severance period described herein with the first
payment to commence on the sixty-first (61st) day following Executive’s termination of employment (and include any severance payments that otherwise would have been paid to Executive within the sixty (60) days following Executive’s
termination date), with any remaining payments paid in accordance with the Company’s normal payroll practices for the remainder of the severance period following Executive’s termination of employment (subject to any delay as may be
required by Section 7(c)). 
 (ii) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act
of 1985, as amended (“COBRA”) within the time period prescribed pursuant to COBRA for Executive and Executive’s eligible dependents, then the Company will reimburse Executive for the COBRA premiums for such coverage (at the
coverage levels in effect immediately prior to Executive’s termination) until the earlier of (A) a period of nine (9) months from the date of termination or (B) the date upon which Executive and/or Executive’s eligible dependents are no
longer eligible for COBRA continuation coverage. The reimbursements will be made by the Company to Executive consistent with the Company’s normal expense reimbursement policy. Notwithstanding the first sentence of this Section 6(a)(ii), if the
Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating, or being subject to an excise tax under, applicable law (including, without limitation, Section 2716 of the Public Health Service
Act), the Company will in lieu thereof provide to Executive a taxable monthly payment, payable on the last day of a given month (except as provided by the following sentence), in an amount equal to the monthly COBRA premium that Executive would be
required to pay to continue the group health coverage for Executive and/or Executive’s eligible dependents in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA coverage), which
payments will be made regardless of whether Executive and/or Executive’s eligible dependents elect COBRA continuation coverage and will commence on the month following Executive’s termination of employment and will end on the earlier of
(x) the date upon which Executive obtains other employment or (y) the date the Company has paid an amount equal to nine (9) payments. Any such taxable monthly payments that otherwise would have been paid to Executive within the sixty (60) days
following Executive’s termination date instead will be paid on the sixty-first (61st) day following Executive’s termination of employment, with any remaining payments paid as provided in the prior sentence (subject to any delay as may be
required by Section 7(c)). For the avoidance of doubt, the taxable payments in lieu of COBRA reimbursements may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax
withholdings. 
 (b) Termination for other than Cause, Death or Disability or Resignation by Executive for Good Reason Related to a
Change of Control. If, within the Change of Control Period (i) the Company (or any parent or subsidiary or successor of the Company) terminates Executive’s 

  
 -3- 

 
employment with the Company other than for Cause, death or Disability, or (ii) the Executive resigns from such employment for Good Reason, then, subject to Section 8, Executive will be entitled
to receive: 
 (i) a lump sum payment equal to one hundred and fifty percent (150%) of the sum of: (A) Executive’s Base Salary, as
then in effect, or if greater, at the level in effect immediately prior to the Change of Control, plus (B) Executive’s Target Bonus in effect for the fiscal year in which Executive’s termination of employment occurs. The severance
will be paid, less applicable withholdings, on the sixty-first (61st) day following Executive’s termination of employment in accordance with the Company’s normal payroll practices (subject to any delay as may be required by Section
7(c)). For the avoidance of doubt, if (x) Executive incurred a termination of employment prior to a Change of Control that qualifies Executive for severance payments under Section 6(a)(i); and (y) a Change of Control occurs within the three
(3)-month period following Executive’s termination of employment that qualifies Executive for the superior benefits under this Section 6(b)(i), then Executive shall be entitled to a lump-sum payment of the amount calculated under this Section
6(b)(i), less amounts already paid under Section 6(a)(i). 
 (ii) if Executive elects continuation coverage pursuant to COBRA within the
time period prescribed pursuant to COBRA for Executive and Executive’s eligible dependents, then the Company will reimburse Executive for the COBRA premiums for such coverage (at the coverage levels in effect immediately prior to
Executive’s termination) until the earlier of (A) a period of eighteen (18) months from the date of termination or (B) the date upon which Executive and/or Executive’s eligible dependents are no longer eligible for COBRA continuation
coverage. The reimbursements will be subject to the same conditions, limitations, and restrictions as the COBRA benefits described in Section 6(a)(ii); provided, however, that if the Company provides Executive a taxable monthly payment in lieu of
COBRA reimbursement, such payment will end on the earlier of (x) the date upon which Executive obtains other employment or (y) the date the Company has paid an amount equal to eighteen (18) payments; and 

(iii) accelerated vesting as to one hundred percent (100%) of Executive’s then-outstanding equity awards to acquire Company common
stock. 
 (c) Termination for Cause, Death or Disability; Resignation without Good Reason. If Executive’s employment with
the Company (or any parent or subsidiary or successor of the Company) terminates voluntarily by Executive (except upon resignation for Good Reason), for Cause by the Company or due to Executive’s death or Disability, then (i) all vesting will
terminate immediately with respect to Executive’s outstanding equity awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (iii) Executive will only
be eligible for severance benefits in accordance with the Company’s established policies, if any, as then in effect. 
 (d)
Exclusive Remedy. In the event of a termination of Executive’s employment with the Company (or any parent or subsidiary or successor of the Company), the provisions of this Section 7 are intended to be and are exclusive and in lieu
of any other rights or remedies to which Executive or the Company may otherwise be entitled, whether at law, tort or contract, in equity, or under this Agreement, including any prior employment agreements entered into between the Company and
Executive. Executive will be entitled to no severance or other benefits upon 

  
 -4- 

 
termination of employment with respect to acceleration of award vesting or severance pay other than those benefits expressly set forth in this Section 7. 

7. Conditions to Receipt of Severance; No Duty to Mitigate.

(a) Separation Agreement and Release of Claims. The receipt of any severance pursuant to Section 6(a) or (b) will be subject to
Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company (the “Release”) and provided that such Release becomes effective and irrevocable no later than sixty
(60) days following the termination date (such deadline, the “Release Deadline”). If the Release does not become effective and irrevocable by the Release Deadline, Executive will forfeit any rights to severance or benefits
under this Agreement. In no event will severance payments or benefits be paid or provided until the Release becomes effective and irrevocable. 

(b) Nonsolicitation. The receipt of any severance benefits pursuant to Section 6(a) or (b) will be subject to Executive not
violating the provisions of Section 11. In the event Executive breaches the provisions of Section 11, all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 6(a) or (b) will immediately cease. 

(c) Section 409A.
 (i)
Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits,
are considered deferred compensation under Code Section 409A, and the final regulations and any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or otherwise provided
until Executive has a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury
Regulation Section 1.409A-1(b)(9) will be payable until Executive has a “separation from service” within the meaning of Section 409A. 

(ii) Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee” within the meaning of
Section 409A at the time of Executive’s termination (other than due to death), then the Deferred Payments that are payable within the first six (6) months following Executive’s separation from service, will become payable on the first
payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive’s separation from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule
applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s separation from service, but prior to the six (6) month anniversary of the separation from service, then any
payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive’s death and all other Deferred Payments will be payable in accordance with the payment schedule
applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 

  
 -5- 

 (iii) Any amount paid under this Agreement that satisfies the requirements of the
“short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above. 

(iv) Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to
Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below) will not constitute Deferred Payments for purposes of clause (i) above. 

(v) The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits
to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to
this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A. Executive agrees and
acknowledges that the Company makes no representations or warranties with respect to the application of Section 409A and other tax consequences to any payments hereunder and, by the acceptance of any such payments, Executive agrees to accept the
potential application of Section 409A and the other tax consequences of any payments made hereunder. 
 (d) Confidential Information
Agreement. Executive’s receipt of any payments or benefits under Section 6 will be subject to Executive continuing to comply with the terms of Confidential Information Agreement (as defined in Section 10). 

(e) No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor
will any earnings that Executive may receive from any other source reduce any such payment. 
 8. Definitions. 

(a) Cause. For purposes of this Agreement, “Cause” is defined as (i) the willful failure, disregard, or refusal
by Executive to perform the services hereunder or follow the reasonable instructions of the Board; provided, however, that any willful failure, disregard, or refusal by Executive to perform the services hereunder that can reasonably be
cured shall not constitute Cause unless cure is not effected, as determined in good faith by the Board, within thirty (30) days after notice thereof is received by the Executive from the Company; (ii) any willful or grossly negligent act by the
Executive having the effect of injuring, in a material way (whether financial or otherwise) as determined in good faith by the Board, the business or reputation of the Company or any of its subsidiaries or affiliates; (iii) Executive’s
conviction of, guilty plea, or plea of nolo contendere to any felony or a misdemeanor involving moral turpitude; (iv) the determination by the Company, after a reasonable and good faith investigation by the Company following a written allegation by
an employee of the Company, that the Executive engaged in some form of harassment prohibited by law (including, without limitation, age, sex, disability, or race discrimination) unless Executive’s actions were specifically directed by the
Board; or (v) material breach by the Executive of any provision of this Agreement or any Confidential Information Agreement. 

  
 -6- 

 (b) Change of Control. For purposes of this Agreement, “Change of
Control” means the occurrence of any of the following events: 
 (i) a change in the ownership of the Company which occurs
on the date that any one person, or more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent
(50%) of the total voting power of the stock of the Company; provided, however, that for purposes of this subsection, the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%) of the
total voting power of the stock of the Company will not be considered a Change in Control; or 
 (ii) a change in the ownership of a
substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets
from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided,
however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company’s assets: (A) a transfer to an entity that is controlled by the Company’s
stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company’s stock,
(2) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total
value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection
(8)(b)(iii). For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.

 For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into
a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 
 Notwithstanding the
foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section 409A, as it has been and may be amended from time to time, and any proposed or final
Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time. 

Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the
state of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such
transaction. 

  
 -7- 

 (c) Change of Control Period. For purposes of this Agreement, “Change of
Control Period” means the period that begins three (3) months prior to a Change of Control and ends twelve (12) months following a Change of Control. 

(d) Code. For purposes of this Agreement, “Code” means the Internal Revenue Code of 1986, as amended. 

(e) Disability. For purposes of this Agreement, “Disability” means that Executive has been unable to engage in
any substantial gainful activity by reason of any medically determinable physical or mental impairment for a period of ninety (90) consecutive days or more, or more than one hundred and eighty (180) days within any twelve (12)-month period, in each
case, determined by the Board. 
 (f) Good Reason. For the purposes of this Agreement, “Good Reason” means
Executive’s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive’s express written consent: (i) a material
breach of any provision of this Agreement by the Company; (ii) any material reduction by the Company of Executive’s duties, responsibilities, or authority; (iii) a material relocation of the Company’s principal place of business of
Executive outside of the San Diego Metropolitan area; or (iv) a material diminution in Executive’s annual base salary. Executive will not resign for Good Reason without first providing the Company with written notice of the acts or
omissions constituting the grounds for “Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of not less than thirty (30) days following the date the Company
receives such notice during which such condition must not have been cured. 
 (g) Section 409A Limit. For purposes of this
Agreement, “Section 409A Limit” will mean two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Executive’s taxable year preceding the
Executive’s taxable year of Executive’s separation from service as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum
amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive’s separation from service occurred. 

9. Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable
to Executive (the “Payments”) (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 9, would be subject to the excise tax imposed by Section 4999 of the Code, then
Executive’s Payments will be either: 
 (a) delivered in full, or 

(b) delivered as to such lesser extent which would result in no portion of such severance benefits being subject to the excise tax under
Section 4999 of the Code, 
 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax
imposed by Section 4999, results in the receipt by Executive on an 

  
 -8- 

 
after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such Payments may be taxable under Section 4999 of the Code. If a reduction in the Payments
constituting “parachute payments” is necessary so that no portion of such Payments is subject to the excise tax under Section 4999 of the Code, the reduction shall occur in the following order: (1) reduction of the cash severance
payments; (2) cancellation of accelerated vesting of equity awards; and (3) reduction of continued employee benefits. In the event that acceleration of vesting of equity award compensation is to be reduced, such acceleration of vesting shall be
cancelled in the reverse order of the date of grant of Executive’s equity awards.
 A nationally recognized certified professional
services firm selected by the Company, the Company’s legal counsel or such other person or entity to which the parties mutually agree (the “Firm”) shall perform the foregoing calculations related to the Excise Tax. The Company
shall bear all expenses with respect to the determinations by the Firm required to be made hereunder. For purposes of making the calculations required by this Section, the Firm may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Code Sections 280G and 4999. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to
make a determination under this Section. The Firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the
date on which Executive’s right to the severance benefits or other payments is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. Any good faith determinations of the
Firm made hereunder shall be final, binding, and conclusive upon the Company and Executive. 
 10. Confidential
Information. Executive agrees to execute the Company’s At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (the “Confidential Information Agreement”) concurrently with the
execution of this Agreement. 
 11. Non-Solicitation. Until the date one (1) year after the termination of Executive’s
employment with the Company for any reason, Executive agrees not, either directly or indirectly, to solicit any employee of the Company (or any parent or subsidiary of the Company) to leave Executive’s employment either for Executive or for any
other entity or person. 
 12. Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs,
executors and legal representatives of Executive upon Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all
purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the
assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other
attempted assignment, transfer, conveyance or other disposition of Executive’s right to compensation or other benefits will be null and void. 

13. Notices. All notices, requests, demands and other communications called for hereunder will be in writing and will be deemed
given (i) on the date of delivery if delivered 

  
 -9- 

 
personally, (ii) one (1) day after being sent by a well established commercial overnight service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt
requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing: 

If to the Company: 
 Pfenex 

10790 Roselle St. 
 San Diego, CA
92121 
 Attn: Chief Executive Officer 

If to Executive: 
 at the last
residential address known by the Company. 
 14. Severability. In the event that any provision hereof becomes or is declared by
a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. 

15. Arbitration. Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any
employee, officer, director, stockholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s service to the Company, shall be subject to arbitration in accordance
with the provisions of the Confidential Information Agreement. 
 16. Integration. This Agreement, along with the Confidential
Information Agreement and the Equity Documents, represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. With respect
to equity awards granted on or after the date of this Agreement, the acceleration of vesting provisions provided herein will apply to such equity awards except to the extent the applicable equity award agreement expressly supersedes this
Agreement. This Agreement may be modified only by agreement of the parties by a written instrument executed by the parties that is designated as an amendment to this Agreement. 

17. Waiver of Breach. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will not
operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement. 
 18. Headings. All
captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement. 
 19.
Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes. 
 20.
Governing Law. This Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions). 

  
 -10- 

 21. Acknowledgment. Executive acknowledges that Executive has had the opportunity to
discuss this matter with and obtain advice from Executive’s private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this
Agreement. 
 22. Counterparts. This Agreement may be executed in counterparts, and each counterpart will have the same force
and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned. 

  
 -11- 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by their duly authorized officers, as of the day and year first above written. 
  

									
	COMPANY:	 		 		 	
				
	PFENEX INC.	 		 		 	
					
	By:	 	 /s/ Bertrand C. Liang
	 		 	Date:	 	 9/26/16

					
	Title:	 	 CEO
	 		 		 	
				
	EXECUTIVE:	 		 		 	
				
	 /s/ Steven S. Sandoval
	 		 	Date:	 	 9/26/16

	Steven S. Sandoval, Sr.	 		 		 	

 [SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT] 

  
 -12- 

 SCHEDULE 1 

[TO BE COMPLETED BY EXECUTIVE, IF APPLICABLE] 

  
 -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]